In addition, inhibition of EZH2 activity with GSK126, a selective EZH2 inhibitor, contributed to the differentiation of hematopoietic progenitor cells into MDSCs in vitro, thereby ameliorating colitis symptoms, whereas depletion of MDSCs exacerbated disease progression (130). Here, EZH2 is linked to colitis.